The present invention relates to a Siphoviridae bacteriophage Str-SUP-2 (Accession number: KCTC 13515BP) isolated from nature and characterized by having the ability to kill Streptococcus suis and having the genome represented by SEQ ID NO: 1, and a method for preventing and treating diseases caused by Streptococcus suis using the composition containing the Siphoviridae bacteriophage Str-SUP-2 as an active ingredient.

Provided herein are methods and compositions for killing a target bacterium with a CRISPR-Cpf1 system. Also disclosed are engineered bacteriophages.

Provided herein are methods and compositions for killing a target bacterium with a CRISPR-Cpf1 system. Also disclosed are engineered bacteriophages.

A medical device, the medical device including a substrate defining a surface; a plasma polymer layer bound to and coating the surface; and a bactericide layer bound to the plasma polymer layer, the plasma polymer layer being between the substrate and the bactericide layer. Also, a method for coating a surface of a substrate of a medical device with a bactericide layer, the method including: exposing the surface to a plasma to form a plasma polymer layer bound to the surface; and binding a bactericide layer to the plasma polymer layer.

A medical device, the medical device including a substrate defining a surface; a plasma polymer layer bound to and coating the surface; and a bactericide layer bound to the plasma polymer layer, the plasma polymer layer being between the substrate and the bactericide layer. Also, a method for coating a surface of a substrate of a medical device with a bactericide layer, the method including: exposing the surface to a plasma to form a plasma polymer layer bound to the surface; and binding a bactericide layer to the plasma polymer layer.

A use of a tail fiber protein in the prevention of Acinetobacter baumannii infections is disclosed. The tail fiber protein from bacteriophages is coated or sprayed on carriers (such as pipelines and medical devices in hospitals) to inhibit biofilm formation of Acinetobacter baumannii and further prevent Acinetobacter baumannii infections.

A use of a tail fiber protein in the prevention of Acinetobacter baumannii infections is disclosed. The tail fiber protein from bacteriophages is coated or sprayed on carriers (such as pipelines and medical devices in hospitals) to inhibit biofilm formation of Acinetobacter baumannii and further prevent Acinetobacter baumannii infections.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

The present disclosure provides new attenuated Pepino mosaic viruses useful in the control of plant disease. Compositions for biological control of plant disease are also provided as well as methods for producing Pepino mosaic virus resistant plants.

The present disclosure provides new attenuated Pepino mosaic viruses useful in the control of plant disease. Compositions for biological control of plant disease are also provided as well as methods for producing Pepino mosaic virus resistant plants.